Cabozantinib is a multi-targeting TKI directed against the receptors of factors involved in tumor growth, angiogenesis, pathological bone remodeling, chemoresistance, and metastatic progression of cancer, such as VEGF, MET, GAS6(AXL), RET, ROS1, TYRO3, MER, KIT (stem cell factor), TRKB, Fms-like tyrosine kinase-3 (FLT3), and TIE-2 (32). The gene discussed is AXL; the disease is neoplasm.